We recently compiled a list of the Top 10 Medical AI Stocks on Wall Street’s Radar. In this article, we are going to take a ...

Queen Mary University of London is delighted to announce the appointment of Professor Julia Hippisley-Cox as the inaugural ...

Mediar Therapeutics is planning to launch a Phase 2 clinical trial in the first half of 2025 to test its IPF therapy MTX-463.

The unsuccessful Phase III results are the latest to suggest that the blockbuster cancer drug is finally bumping up against ...

Dyne Therapeutics is a clinical stage biotech concern with just over $700 million of cash on its balance sheet. Learn more ...

The trial tested amycretin in its injectable form, but Novo Nordisk is also separately developing the drug in pill form. Investors cheered an early trial of the pill early last year that showed weight ...

A Lloyd's of London company partnered with GATC Health to fund and insure prospective drug trials that pass the test of a new AI technology.

Dr. Saef Izzy, Associate Professor of Neurology at Harvard Medical School, commented, “Treatment with nasal anti-CD3 not only dampened microglial activation but also led to marked improvements in ...

In the final stretch of the Biden administration, the Food and Drug Administration (FDA) laid the groundwork for continued engagement with the ...

According to a 2023 PwC report, the AI market in healthcare was valued at $11 billion and is expected to grow to $188 billion by 2030. On January 21st, Oracle Co-founder Larry Ellison said during a ...

The phage therapy market is experiencing significant growth due to the increasing prevalence of antibiotic-resistant infections and the growing interest in alternative treatments. Advances in ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...